Published ahead of print on March 16, 2006, doi:10.1165/rcmb.2005-0115OC
Am. J. Respir. Cell Mol. Biol., Volume 35, Number 2, August 2006, 182-189
A more recent version of this article appeared on August 1, 2006
Submitted on March 23, 2005
Revised on March 16, 2006
Microvascular Regeneration in Established Pulmonary Hypertension by Angiogenic Gene Transfer
Yidan D Zhao1, David W Courtman2, Douglas S Ng2, Malcolm J Robb2, Yupu P Deng2, Judy Trogadis2, Robin N.N. Han2, and Duncan J Stewart2*
1 Department of Pharmacology, University of Illinois, Chicago, IL, USA,
2 Cardiology Lab, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
* To whom correspondence should be addressed. E-mail: stewartd{at}smh.toronto.on.ca.
Pulmonary arterial hypertension (PAH) is characterized by widespread loss of pulmonary microvasculature. Therefore we hypothesized that angiogenic gene therapy would reverse established PAH, in part restoring the lung microcirculation.
Methods and Results: Three weeks after monocrotaline (MCT) treatment, Fisher 344 rats were randomized to receive a total of either 1.5 x 106 syngeneic fibroblasts (FB) transfected with vascular endothelial growth factor A (VEGF), endothelial NO-synthase (eNOS), or null-plasmid transfected FBs. Right ventricular systolic pressure (RVSP) was similarly increased in all MCT-treated groups at the time of gene transfer. Animals receiving the null-vector progressed to severe PAH by day 35 (p<0.001). In contrast, eNOS gene transfer significantly reduced RVSP at day 35 compared to day 21, whereas VEGF prevented further increases in RVSP over the subsequent 2 weeks but did not reverse established PAH. RV hypertrophy was significantly reduced in both the eNOStreated and VEGF-treated groups compared with the null-transfected controls. Fluorescent microangiography revealed widespread occlusion of the pre-capillary arterioles 21 days after MCT treatment, and animals receiving eNOS gene transfer exhibited the greatest improvement in the arteriolar architecture and capillary perfusion at day 35.
Conclusions: Cell-based eNOS gene transfer was more effective than VEGF in reversing established PAH, associated with evidence of regeneration of pulmonary microcirculation.
This article has been cited by other articles:

|
 |

|
 |
 
S. Umar, Y. P. de Visser, P. Steendijk, C. I. Schutte, E. H. Laghmani, G. T. M. Wagenaar, W. H. Bax, E. Mantikou, D. A. Pijnappels, D. E. Atsma, et al.
Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension
Am J Physiol Heart Circ Physiol,
November 1, 2009;
297(5):
H1606 - H1616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Lee, R. Reich, F. Xu, and P. B. Sehgal
Golgi, trafficking, and mitosis dysfunctions in pulmonary arterial endothelial cells exposed to monocrotaline pyrrole and NO scavenging
Am J Physiol Lung Cell Mol Physiol,
October 1, 2009;
297(4):
L715 - L728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Ghofrani, R. J. Barst, R. L. Benza, H. C. Champion, K. A. Fagan, F. Grimminger, M. Humbert, G. Simonneau, D. J. Stewart, C. Ventura, et al.
Future perspectives for the treatment of pulmonary arterial hypertension.
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1 Suppl):
S108 - S117.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Beghetti and N. Galie
Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
J. Am. Coll. Cardiol.,
March 3, 2009;
53(9):
733 - 740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. Ramos, M. W. Lame, H. J. Segall, and D. W. Wilson
Smad Signaling in the Rat Model of Monocrotaline Pulmonary Hypertension
Toxicol Pathol,
February 1, 2008;
36(2):
311 - 320.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Gien, G. J. Seedorf, V. Balasubramaniam, N. Markham, and S. H. Abman
Intrauterine Pulmonary Hypertension Impairs Angiogenesis In Vitro: Role of Vascular Endothelial Growth Factor Nitric Oxide Signaling
Am. J. Respir. Crit. Care Med.,
December 1, 2007;
176(11):
1146 - 1153.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Wong, A. E. Dutly, A. Sacher, H. Lee, D. M. Hwang, M. Liu, S. Keshavjee, J. Hu, and T. K. Waddell
Targeted cell replacement with bone marrow cells for airway epithelial regeneration
Am J Physiol Lung Cell Mol Physiol,
September 1, 2007;
293(3):
L740 - L752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. B. Sehgal, S. Mukhopadhyay, F. Xu, K. Patel, and M. Shah
Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol,
June 1, 2007;
292(6):
L1526 - L1542.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. McCarter, S. H. J. Mei, P. F. H. Lai, Q. W. Zhang, C. H. Parker, R. S. Suen, R. D. Hood, Y. D. Zhao, Y. Deng, R. N. N. Han, et al.
Cell-based Angiopoietin-1 Gene Therapy for Acute Lung Injury
Am. J. Respir. Crit. Care Med.,
May 15, 2007;
175(10):
1014 - 1026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Distler and A. Pignone
Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment
Rheumatology,
October 1, 2006;
45(suppl_4):
iv22 - iv25.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 American Thoracic Society.
|
|
|